Skip to content

Anti-ageing and anti-inflammatory activity of Miror Revive tablets

An open label, Clinical study to Evaluate the anti-ageing and anti-inflammatory activity of Miror Revive tablets - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/095362
Enrollment
40
Registered
2025-09-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product: Miror Revive Tablets: Test Product: Miror Revive tablets, Dose: 1 Tablet after breakfast (OD), Route of Administration: Oral, test duration: 30 days Intervention2: Not Ap

Sponsors

Miror Therapeutics Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Females from 30-55 years of age. 2. Females having Ageing (Fine Lines, Wrinkles, Age spots etc.) will be eligible for enrollment. 3. Subjects that are able to give written informed consent in a manner approved by the institutional ethics committee and comply with the requirements of the study. 4. Subject willing to avoid participation in any other interventional clinical trial for the duration of the study.

Exclusion criteria

Exclusion criteria: 1. Have used, are using, or are planning to use immunosuppressive or immunomodulatory medication (i.e., biologics), including oral or parenteral corticosteroids. 2. Subjects that have participated in any other interventional clinical trial in the previous 90 days. 3. Subjects with known sensitivity to any of the constituents of the investigational product. 4. Any clinically significant systemic or cutaneous disease, which may interfere with study treatment or procedures. 5. Chronic illness which may influence the outcome of the study. 6. Pregnant/nursing mothers

Design outcomes

Primary

MeasureTime frame
1. change in skin hydration 2. change in TEWL 3. Change in Skin firmness 4. change in C-Reactive Protein (CRP) 5. Erythrocyte Sedimentation Rate (ESR)Timepoint: At T0 and T30Days

Secondary

MeasureTime frame
1. SGA 2. Change in CASP-19(Control, Autonomy, Self-realization, and Pleasure-19)Timepoint: At Day1 and 30 day

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org08937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026